Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options
Current Oncology · 2025
DOI: 10.3390/curroncol32110648 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Jacob C Easaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine & Dentistry, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada. Hauptthemen laut MEDLINE: Claudins, Immunotherapy, Stomach Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma remains a common and deadly form of cancer. Advances in G/GEJ cancer treatment have improved survival outcomes with the claudin-18.2 (CLDN18.2)-targeted agent, zolbetuximab, and immune checkpoint inhibitors (ICIs) targeting the PD-1 receptor. This article offers an evidence-informed opinion on considerations when selecting between these first-line treatments for G/GEJ adenocarcinoma in patients with HER2-negative disease that expresses CLDN18.2 and/or PD-L1, including the reliability of biomarker scoring and interpretation, overall survival (OS) rates, toxicity profiles, and logistical practicalities. Evidence from Phase III trials for zolbetuximab and ICIs suggest similar OS benefits of 14–18 months compared to chemotherapy alone, but there appears to be a gradient of benefit for ICIs with increasing PD-L1 combined positive score (CPS). There is high inter-observer variability in CPS scoring, particularly at lower thresholds. Zolbetuximab is associated with high rates of nausea and vomiting during the initial infusion, whereas ICIs are associated with risk of later-onset immune-related toxicities that can be fatal in rare cases. In considering the available evidence, our opinion is that zolbetuximab is a reasonable option for initial targeted treatment in HER2-/CLDN18.2-positive advanced G/GEJ when PD-L1 CPS score is
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine & Dentistry, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Division of Medical Oncology, Faculty of Medicine, University of British Columbia and Systemic Therapy BC Cancer, Vancouver, BC V5Z 4E6, Canada.
- Division of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Center, Calgary, AB T2N 5G2, Canada.
- Faculty of Medicine & Dentistry, Laboratory Medicine & Pathology Department, University of Alberta, Edmonton, AB T6G 1C9, Canada.
ORCID-Profile: Jacob C Easaw, Sharlene Gill
Zitieren
APA
Easaw, J. C., Lim, H. J., Karachiwala, H., Gill, S., Zhu, X., & Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology. https://doi.org/10.3390/curroncol32110648
Vancouver
Easaw JC, Lim HJ, Karachiwala H, Gill S, Zhu X, Bateman J. Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Current Oncology. 2025. doi:10.3390/curroncol32110648
BibTeX
@article{Easaw2025,
author = {Easaw, Jacob C and Lim, Howard J and Karachiwala, Hatim and Gill, Sharlene and Zhu, Xiaofu and Bateman, Justin},
title = {Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32110648}
}
EUVIMED